Trusted Outcomes
Delivering real-world evidence
Outcomes you can trust
10-year
On-going-follow-up
The Global Registry for Endovascular Aortic Treatment (GREAT) is a comprehensive registry encompassing 28 aortic pathologies. With a 10-year patient follow-up, it provides trustworthy long-term results. The registry consists of real-world data from over 5,000 patients resulting in over 30 peer-reviewed publications in the past decade.
Over 30
Peer-reviewed publications
This, coupled with more than 25 years of clinical experience with aortic devices and over 20 years patient follow-up,1 offers an outstanding data pool. It supports health care providers with insights that can improve clinical decision making.
The major value of the GREAT Registry is having the opportunity to report on the very long-term follow-up, up to 10 years on more than 5,000 patients affected by thoracic and abdominal aortic disease.
This data includes procedural and clinical outcomes, covering 28 different pathologies along the aorta, as well as information on the devices used, patient medical history, demographics and disease state.
The ability to track such a large number of patients over an extended period of time is something that clearly sets GREAT apart from other registries. This sample will provide us with an opportunity to measure patient successes and outcomes that help us make continued improvements in aortic endovascular repair.
The largest registry in the aortic field
Dennis R. Gable, M.D.
Ross Milner, M.D.
Device construction, materials and stent design all have significant impact on the overall outcome of aortic procedures. The GORE® EXCLUDER® AAA Endoprosthesis demonstrates this importance with its proven track record of 0.1% migration and fracture rates along with very low type I, III and IV endoleak rates.2
Long-term durability for TEVAR and EVAR
TEVAR 85.5%
freedom from device-related reinterventions with the Conformable GORE® TAG® Thoracic Endoprosthesis* through 5-year follow-up
| TEVAR | |
|---|---|
| Procedural | |
| Patients ° | 778 |
| Procedural survival | 99.7% |
| Access complication | 2.8% |
| Through 5 years | |
| Migration | 0.3% |
| Fracture | 0% |
| Compression | 0% |
| Conversion to open repair | 1.8% |
| Aortic-related mortality | 3% |
EVAR 94.7%
freedom from device-related reinterventions with GORE® EXCLUDER® AAA Endoprosthesis† through 5-year follow-up
| EVAR | |
|---|---|
| Through 5 years | |
| Patients ° | 3,216 |
| Migration | 0.1% |
| Type 1 A endoleak | 1.1% |
| Type III endoleak | 0.2% |
| Conversion to open repair | 0.9% |
| Aortic-related mortality | 1.2% |
| Limb occlusion | 0.7% |
* W. L. Gore & Associates. 'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation. Bethesda, MD: National Library of Medicine; 2012. Available from: NLM Identifier: NCT01658787. Published August 7, 2012. Updated: September 29, 2021. Accessed June 7, 2022. https://clinicaltrials.gov/ct2/show/NCT01658787
† GREAT. n = 4,997. To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events.
- Van Gool F, Houthoofd S, Mufty H, Bonne L, Fourneau I, Maleux G. Long-term outcome results after endovascular aortoiliac aneurysm repair with the bifurcated EXCLUDER Endoprosthesis. J Vasc Surg. 2022;75(6):1882-1889.
- Long C, Katsargyris A, Milner R, Verhoeven E. Five-year results for abdominal aortic aneurysm repair with the GORE® EXCLUDER® device: Insights from the Gore Global Registry for Endovascular Aortic Treatment (GREAT). Annals of Vascular Surgery 2024;106:247-254.
Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
GORE® EXCLUDER® AAA Endoprosthesis
INDICATIONS FOR USE IN EUROPE:
Trunk-Ipsilateral Leg Endoprosthesis and Contralateral Leg Endoprosthesis Components
The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below:
- Adequate iliac / femoral access
- Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm
- Proximal aortic neck angulation ≤ 60°
- Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm
Aortic Extender Endoprosthesis and Iliac Extender Endoprosthesis Components
The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and / or sealing for aneurysmal exclusion is desired.
CONTRAINDICATIONS: The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in:
- Patients with known sensitivities or allergies to the device materials
- Patients with a systemic infection who may be at increased risk of endovascular graft infection
GORE® TAG® Conformable Thoracic Stent Graft
INDICATIONS FOR USE IN EUROPE: The GORE® TAG® Conformable Thoracic Stent Graft is indicated for endovascular repair of all lesions of the descending thoracic aorta, including isolated lesions, such as aneurysm and traumatic transection, and Type B dissections.
CONTRAINDICATIONS: The GORE® TAG® Conformable Thoracic Stent Graft is contraindicated in:
- Patients with known sensitivities or allergies to the device materials
- Patients with a systemic infection who may be at risk of endovascular graft infection